-
BGLC Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
-
ETFs
-
Insider
- Institutional
- Shorts
BioNexus Gene Lab (BGLC)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.14 mm | 4.14 mm | 4.14 mm | 4.14 mm | 4.14 mm | 4.14 mm |
Cash burn (monthly) | 425.60 k | 167.47 k | 447.94 k | 75.88 k | 486.50 k | 202.20 k |
Cash used (since last report) | 1.72 mm | 675.09 k | 1.81 mm | 305.89 k | 1.96 mm | 815.08 k |
Cash remaining | 2.42 mm | 3.46 mm | 2.33 mm | 3.83 mm | 2.18 mm | 3.32 mm |
Runway (months of cash) | 5.7 | 20.7 | 5.2 | 50.5 | 4.5 | 16.4 |
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Proequities | 0.00 | $0.00 |